Mozhgan Foroutan Kahangi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mozhgan Foroutan Kahangi has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Ehsan Nazemalhosseini-Mojarad
Gastroenterology and Liver Diseases Research center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
1 shared publication - Fatemeh Kouhkan
Stem Cell Technology Research Center, Tehran, Iran
1 shared publication - Iman Samiei Mosleh
Plant Functional Genomics Lab, Institute of Molecular Biotechnology, Department of Biotechnology, BOKU University, Vienna, Austria
1 shared publication - Moein Piroozkhah
Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
1 shared publication - Mohammad Rostami-Nejad
Celiac Disease and Gluten-Related Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
1 shared publication - Nastaran Asri
Celiac Disease and Gluten Related Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
1 shared publication
Latest Publications
- Open Access
- 1 January 2025
- Published by Wiley in Analytical Cellular Pathology
- Vol. 2025 (1)
Toward Precision Medicine in Celiac Disease: Emerging Roles of Multiomics and Artificial Intelligence
This paper focuses on celiac disease (CD), an autoimmune disorder characterized by small intestinal enteropathy and gastrointestinal symptoms. The prevalence of CD is rising, and there is a need for prompt and accurate diagnosis. The paper discusses the challenges in classifying CD and the consequences of delayed diagnosis, including increased morbidity and mortality rates. It also highlights the Marsh classification, which categorizes CD based on histological characteristics. However, this classification has limitations, which can lead to misdiagnosis. The emergence of multiomics data and artificial intelligence (AI) is presented as a potential solution to improve CD diagnosis and management. Multiomics data integration enables a more precise diagnosis, while AI and machine learning (ML) techniques facilitate the identification of clinically relevant patterns and the development of diagnostic models. According to the findings, the integration of AI and multiomics data holds transformative potential for the diagnosis and management of CD, facilitating early diagnosis and personalized treatment strategies. AI‐assisted methods, including video capsule endoscopy (VCE) analysis, have shown sensitivities exceeding 90%, enhancing diagnostic accuracy while reducing invasiveness. As novel biomarkers are identified, individualized management approaches can evolve, leading to improved patient outcomes, though further efforts are needed to standardize these technologies in clinical practice.
- 1 January 2025
- Published by Wiley in Analytical Cellular Pathology
- Vol. 2025 (1)
Open AccessToward Precision Medicine in Celiac Disease: Emerging Roles of Multiomics and Artificial Intelligence
This paper focuses on celiac disease (CD), an autoimmune disorder characterized by small intestinal enteropathy and gastrointestinal symptoms. The prevalence of CD is rising, and there is a need for prompt and accurate diagnosis. The paper discusses the challenges in classifying CD and the consequences of delayed diagnosis, including increased morbidity and mortality rates. It also highlights the Marsh classification, which categorizes CD based on histological characteristics. However, this classification has limitations, which can lead to misdiagnosis. The emergence of multiomics data and artificial intelligence (AI) is presented as a potential solution to improve CD diagnosis and management. Multiomics data integration enables a more precise diagnosis, while AI and machine learning (ML) techniques facilitate the identification of clinically relevant patterns and the development of diagnostic models. According to the findings, the integration of AI and multiomics data holds transformative potential for the diagnosis and management of CD, facilitating early diagnosis and personalized treatment strategies. AI‐assisted methods, including video capsule endoscopy (VCE) analysis, have shown sensitivities exceeding 90%, enhancing diagnostic accuracy while reducing invasiveness. As novel biomarkers are identified, individualized management approaches can evolve, leading to improved patient outcomes, though further efforts are needed to standardize these technologies in clinical practice.
- 27 August 2024
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 39 (7) , 1269-1281
Involvement of oncomiRs miR-23, miR-24, and miR-27 in the regulation of alternative polyadenylation in glioblastoma via CFIm25 cleavage factor
Glioblastoma multiforme (GBM) is a highly aggressive brain tumor with a poor prognosis. The cleavage factor Im 25 (CFIm25), a crucial component of the CFIm complex, plays a key role in regulating the length of the mRNA 3’-UTR and has been implicated in various cancers, including GBM. This study sought to investigate the regulatory influence of specific microRNAs (miRNAs) on CFIm25 expression in GBM, a highly aggressive brain tumor. Bioinformatics analysis identified miRNA candidates targeting CFIm25 mRNA, and gene expression profiles from the NCBI database (GSE90603) were used for further analysis. Expression levels of CFIm25 and selected miRNAs were assessed using qRT-PCR in GBM clinical samples (n = 20) and non-malignant brain tissues (n = 5). Additionally, the MTT assay was performed to examine the effect of miRNA overexpression on U251 cell viability. Lentivectors expressing the identified miRNAs were employed to experimentally validate their regulatory role on CFIm25 in U251 cell lines, and Western blot analysis was conducted to determine CFIm25 protein levels. We observed significantly increased levels of miR-23, miR-24, and miR-27 expression, associated with a marked reduction in CFIm25 expression in GBM samples compared to non-malignant brain tissues. In particular, overexpression of miR-23, miR-24, and miR-27 in U251 cells resulted in CFIm25 downregulation at both the mRNA and protein levels, while their inhibition increased CFIm25 and reduced cell proliferation. These observations strongly implicate miR-23, miR-24, and miR-27 in regulating CFIm25 expression in GBM, emphasizing their potential as promising therapeutic targets for enhancing treatment responses in glioblastoma.
- 27 August 2024
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 39 (7) , 1269-1281
Involvement of oncomiRs miR-23, miR-24, and miR-27 in the regulation of alternative polyadenylation in glioblastoma via CFIm25 cleavage factor
Glioblastoma multiforme (GBM) is a highly aggressive brain tumor with a poor prognosis. The cleavage factor Im 25 (CFIm25), a crucial component of the CFIm complex, plays a key role in regulating the length of the mRNA 3’-UTR and has been implicated in various cancers, including GBM. This study sought to investigate the regulatory influence of specific microRNAs (miRNAs) on CFIm25 expression in GBM, a highly aggressive brain tumor. Bioinformatics analysis identified miRNA candidates targeting CFIm25 mRNA, and gene expression profiles from the NCBI database (GSE90603) were used for further analysis. Expression levels of CFIm25 and selected miRNAs were assessed using qRT-PCR in GBM clinical samples (n = 20) and non-malignant brain tissues (n = 5). Additionally, the MTT assay was performed to examine the effect of miRNA overexpression on U251 cell viability. Lentivectors expressing the identified miRNAs were employed to experimentally validate their regulatory role on CFIm25 in U251 cell lines, and Western blot analysis was conducted to determine CFIm25 protein levels. We observed significantly increased levels of miR-23, miR-24, and miR-27 expression, associated with a marked reduction in CFIm25 expression in GBM samples compared to non-malignant brain tissues. In particular, overexpression of miR-23, miR-24, and miR-27 in U251 cells resulted in CFIm25 downregulation at both the mRNA and protein levels, while their inhibition increased CFIm25 and reduced cell proliferation. These observations strongly implicate miR-23, miR-24, and miR-27 in regulating CFIm25 expression in GBM, emphasizing their potential as promising therapeutic targets for enhancing treatment responses in glioblastoma.